202 related articles for article (PubMed ID: 34084399)
1. Sulfatase-cleavable linkers for antibody-drug conjugates.
Bargh JD; Walsh SJ; Isidro-Llobet A; Omarjee S; Carroll JS; Spring DR
Chem Sci; 2020 Jan; 11(9):2375-2380. PubMed ID: 34084399
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin cleavable ADC linkers.
Gray ME; Zielinski KM; Xu F; Elder KK; McKay SJ; Ojo VT; Benjamin SR; Yaseen AA; Brooks TA; Tumey LN
Xenobiotica; 2024 May; ():1-13. PubMed ID: 38738708
[TBL] [Abstract][Full Text] [Related]
3. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
[TBL] [Abstract][Full Text] [Related]
4. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
5. Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers.
Miller JT; Vitro CN; Fang S; Benjamin SR; Tumey LN
Bioconjug Chem; 2021 Apr; 32(4):842-858. PubMed ID: 33788548
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety.
Wang Y; Liu L; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245171
[TBL] [Abstract][Full Text] [Related]
7. Azobenzene-Based Linker Strategy for Selective Activation of Antibody-Drug Conjugates.
Xiao D; Liu L; Xie F; Dong J; Wang Y; Xu X; Zhong W; Deng H; Zhou X; Li S
Angew Chem Int Ed Engl; 2024 Apr; 63(16):e202310318. PubMed ID: 38369681
[TBL] [Abstract][Full Text] [Related]
8. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency.
Dovgan I; Ehkirch A; Lehot V; Kuhn I; Koniev O; Kolodych S; Hentz A; Ripoll M; Ursuegui S; Nothisen M; Cianférani S; Wagner A
Sci Rep; 2020 May; 10(1):7691. PubMed ID: 32376903
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers.
Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R
Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629
[TBL] [Abstract][Full Text] [Related]
10. Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.
Chuprakov S; Ogunkoya AO; Barfield RM; Bauzon M; Hickle C; Kim YC; Yeo D; Zhang F; Rabuka D; Drake PM
Bioconjug Chem; 2021 Apr; 32(4):746-754. PubMed ID: 33689309
[TBL] [Abstract][Full Text] [Related]
11. Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
Balamkundu S; Liu CF
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002080
[TBL] [Abstract][Full Text] [Related]
12. Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy.
Wang Y; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31288450
[TBL] [Abstract][Full Text] [Related]
13. Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.
Dal Corso A; Cazzamalli S; Gébleux R; Mattarella M; Neri D
Bioconjug Chem; 2017 Jul; 28(7):1826-1833. PubMed ID: 28662334
[TBL] [Abstract][Full Text] [Related]
14. Antibody drug conjugates beyond cytotoxic payloads.
Hobson AD
Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
16. Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.
Wei C; Zhang G; Clark T; Barletta F; Tumey LN; Rago B; Hansel S; Han X
Anal Chem; 2016 May; 88(9):4979-86. PubMed ID: 27075639
[TBL] [Abstract][Full Text] [Related]
17. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.
Sheyi R; de la Torre BG; Albericio F
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214128
[TBL] [Abstract][Full Text] [Related]
18. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.
Anami Y; Xiong W; Gui X; Deng M; Zhang CC; Zhang N; An Z; Tsuchikama K
Org Biomol Chem; 2017 Jul; 15(26):5635-5642. PubMed ID: 28649690
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.
Harel ET; Drake PM; Barfield RM; Lui I; Farr-Jones S; Van't Veer L; Gartner ZJ; Green EM; Lourenço AL; Cheng Y; Hann BC; Rabuka D; Craik CS
Antibodies (Basel); 2019 Nov; 8(4):. PubMed ID: 31694242
[TBL] [Abstract][Full Text] [Related]
20. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N
Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
